clinical trial · NCT06088784
A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants
HanAll BioPharma Co., Ltd.·phase1·completed·n = 76
Healthy VolunteersATH-399APlaceboATH-399A 10 mg5 mg ATH-399A capsule20mg ATH-399A capsule40mg ATH-399A capsule80mg ATH-399A capsule
brief summary
This study will evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of ATH-399A in healthy adults and also evaluate the effect of food on ATH-399A in order to develop mechanism-based and/or disease-modifying treatments for Parkinson Disease.
started
Sep 19, 2023
primary completion
Apr 24, 2024
completion
Apr 24, 2024
last updated
Dec 19, 2025
official title
A Randomized, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses as Well as the Food Effect of Orally Administered ATH-399A in Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol